4RE1

Crystal structure of human TEAD1 and disulfide-engineered YAP


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.2 Å
  • R-Value Free: 0.248 
  • R-Value Work: 0.212 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.

Zhou, Z.Hu, T.Xu, Z.Lin, Z.Zhang, Z.Feng, T.Zhu, L.Rong, Y.Shen, H.Luk, J.M.Zhang, X.Qin, N.

(2015) Faseb J. 29: 724-732

  • DOI: 10.1096/fj.14-262980

  • PubMed Abstract: 
  • Hippo signaling pathway is emerging as a novel target for anticancer therapy because it plays key roles in organ size control and tumorigenesis. As the downstream effectors, Yes-associated protein (YAP)-transcriptional enhancer activation domain fami ...

    Hippo signaling pathway is emerging as a novel target for anticancer therapy because it plays key roles in organ size control and tumorigenesis. As the downstream effectors, Yes-associated protein (YAP)-transcriptional enhancer activation domain family member (TEAD) association is essential for YAP-driven oncogenic activity, while TEAD is largely dispensable for normal tissue growth. We present the design of YAP-like peptides (17mer) to occupy the interface 3 on TEAD. Introducing cysteines at YAP sites 87 and 96 can induce disulfide formation, as confirmed by crystallography. The engineered peptide significantly improves the potency in disrupting YAP-TEAD interaction in vitro. To confirm that blocking YAP-TEAD complex formation by directly targeting on TEAD is a valid approach, we report a significant reduction in tumor growth rate in a hepatocellular carcinoma xenograft model after introducing the dominant-negative mutation (Y406H) of TEAD1 to abolish YAP-TEAD interaction. Our results suggest that targeting TEAD is a promising strategy against YAP-induced oncogenesis.


    Organizational Affiliation

    *Discovery Technology, Medicinal Chemistry, and Discovery Oncology, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China joe.zhou.jz2@roche.com.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Transcriptional enhancer factor TEF-1
A, B
220Homo sapiensMutation(s): 0 
Gene Names: TEAD1 (TCF13, TEF1)
Find proteins for P28347 (Homo sapiens)
Go to Gene View: TEAD1
Go to UniProtKB:  P28347
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Yorkie homolog
C, D
149Homo sapiensMutation(s): 4 
Gene Names: YAP1 (YAP65)
Find proteins for P46937 (Homo sapiens)
Go to Gene View: YAP1
Go to UniProtKB:  P46937
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CL
Query on CL

Download SDF File 
Download CCD File 
A
CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.2 Å
  • R-Value Free: 0.248 
  • R-Value Work: 0.212 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 44.250α = 90.00
b = 105.030β = 90.00
c = 164.780γ = 90.00
Software Package:
Software NamePurpose
Aimlessdata scaling
Blu-Icedata collection
PHASERphasing
MOSFLMdata reduction
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2014-09-21 
  • Released Date: 2014-11-19 
  • Deposition Author(s): Xu, Z., Zhou, Z.

Revision History 

  • Version 1.0: 2014-11-19
    Type: Initial release
  • Version 1.1: 2015-09-02
    Type: Database references